Tuesday, 7 July 2015
Last updated 4 hours ago
Mar 23 2010 | 12:20pm ET
To prevent a third proxy battle with Carl Icahn in three years, biotechnology company Biogen Idec has agreed to give the activist hedge fund manager a third seat on its board of directors.
Under the deal with Icahn, cancer specialist Eric Rowinsky will join Biogen’s board, alongside Alexander Denner, managing director of Icahn Partners, and Harvard Medical School genetics professor Richard Mulligan, Icahn nominees elected to the board last year.
For his part, Icahn has agreed to withdraw his three nominees to the board this year and the hedge fund will vote its shares for the management slate.
May 27 2015 | 2:15pm ET
Support Hedge Funds Care, also known as Help For Children (HFC), by participating in this year's raffle. All proceeds go to support HFC's mission of preventing and treating child abuse. Read more…